Cytek Biosciences, Inc. Common Stock (CTKB) is a publicly traded Healthcare sector company. As of May 21, 2026, CTKB trades at $3.77 with a market cap of $458.46M and a P/E ratio of 0.00. CTKB moved +5.88% today. Year to date, CTKB is -27.64%; over the trailing twelve months it is +41.73%. Its 52-week range spans $2.37 to $7.63. Analyst consensus is buy with an average price target of $5.34. Rallies surfaces CTKB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cytek Biosciences Delivers Record Q4 Revenue of $62.1M, Guides $205–212M for 2026: Cytek Biosciences reported Q4 2025 revenue of $62.1 million, up 8% year-over-year and its highest quarterly revenue, driven by double-digit growth in EMEA and APAC and a 208-unit installed-base expansion to 3,664 units. The company ended 2025 with $261.5 million cash, repurchased $15.1 million stock and set 2026 revenue guidance of $205–212 million.
| Metric | Value |
|---|---|
| Price | $3.77 |
| Market Cap | $458.46M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.63 |
| 52-Week Low | $2.37 |
| Volume | 105 |
| Avg Volume | 0 |
| Revenue (TTM) | $204.17M |
| Net Income | $-74.00M |
| Gross Margin | 51.70% |
4 analysts cover CTKB: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.34.